Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Cancer: early-phase trial registry
89 of 260 indexed Head and Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #39 of 28,707 conditions by registered trial count.
260 US clinical trials · 89 currently recruiting · #39 of 28,707 conditions by registered trial count
Head and Neck Cancer: 260 US clinical trials tracked, 89 recruiting.
Head and Neck Cancer is the subject of 260 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 137 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition head-and-neck-cancer
OPEN 89 | RECR 34% | LATE 13 | EARLY 137 | RANK #39 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Recurrent Malignant Solid Neoplasm (34% recruiting · 38 trials)
Head and Neck Cancer lists 89 open slots (34% of 260 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Cancer is recruiting below its size-band peers.
89 of 260 indexed trials (34.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 19 of 260 trials (7.3%). 124 distinct sponsors appear on at least one study for this condition label.
-
Most Head and Neck Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 251 trials that report a genuine target (sentinel values excluded). 165 of those (65.7%) plan for fewer than 100 participants.
-
Head and Neck Cancer research is mostly interventional.
213 interventional and 47 observational studies make up this index (81.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
260 total, page 5 of 6
Nutritional Risk and Mucositis in Patients With Head and Neck Carcinoma Receiving Chemoradiation
University of Arkansas
NCT00577902
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT00833261
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
University of Miami
NCT00003582
Pemetrexed (Alimta) in Patients With Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
NCT00507858
Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer
MedImmune
NCT03162224
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
NCT01358097
Curcumin Biomarker Trial in Head and Neck Cancer
Louisiana State University Health Sciences Center Shreveport
NCT01160302
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
University of Miami
NCT03435471
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Massachusetts General Hospital
NCT02594696
MRI for Eval Tumor & Node Response & Normal Tissue Function to Concurrent Chemo & Radiation Therapy in H&N Cancer (GCC1043)
University of Maryland, Baltimore
NCT01768442
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT00968435
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
NCT00004048
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
Fox Chase Cancer Center
NCT00021333
Study of KeraStat Cream for Radiation Dermatitis During Head and Neck Radiotherapy
Wake Forest University Health Sciences
NCT04173247
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
David M. Brizel, MD
NCT00140556
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
NCT00095836
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Memorial Sloan Kettering Cancer Center
NCT02572869
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03878979
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
NCT00060242
Topical Antisepsis in Head and Neck Cancer Surgery
Medical College of Wisconsin
NCT04721626
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
M.D. Anderson Cancer Center
NCT01432132
Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Vanderbilt-Ingram Cancer Center
NCT00897793
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
NCT00061906
A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer
M.D. Anderson Cancer Center
NCT00490282
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Baylor College of Medicine
NCT00609219
Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps
Icahn School of Medicine at Mount Sinai
NCT03349034
Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients
University of Louisville
NCT01874860
Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy
Vanderbilt-Ingram Cancer Center
NCT02324881
A Study Using Cone Beam CT for Head and Neck Cancer
University of Michigan Rogel Cancer Center
NCT01661062
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
NCT00052611
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine
NCT05678348
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
Fox Chase Cancer Center
NCT00003264
Chemotherapy Plus Radiation Therapy in Treating Patients With Squamous Cell Cancer of the Head and Neck
Dana-Farber Cancer Institute
NCT00003200
Lapatinib and Cetuximab in Patients With Solid Tumors
Georgetown University
NCT01184482
Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients
University of California, San Francisco
NCT01930435
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Poniard Pharmaceuticals
NCT00465725
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
NCT00703638
Comprehensive Assessment of Head and Neck Cancer Survivors
Jay F. Piccirillo, MD
NCT01222481
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
Presage Biosciences
NCT04065555
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
Curis
NCT01384799
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck
Nanospectra Biosciences
NCT00848042
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
University of California, San Diego
NCT03993353
Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
David A. Clump, MD, PhD
NCT02516969
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma
The University of Texas Health Science Center at San Antonio
NCT01592721
Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer
M.D. Anderson Cancer Center
NCT00113334
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
New Mexico Cancer Research Alliance
NCT01275183
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
NCT00984074
Capecitabine For Nasopharyngeal Cancer
Dana-Farber Cancer Institute
NCT00095901
Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer
UNC Lineberger Comprehensive Cancer Center
NCT01688323
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
M.D. Anderson Cancer Center
NCT01030497
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 63 |
| Phase 2 | 74 |
| Phase 3 | 11 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Cancer page
260 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Head and Neck Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Head and Neck Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Cancer condition card totals 260 registered trials; most-linked intervention cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.